Semaglutide at a dose of 2.4 mg has established weight-loss and cardiovascular benefits, and cagrilintide at a dose of 2.4 mg ...

A new clinical trial found that taking a popular diabetes and weight-loss drug once weekly significantly improves blood sugar ...

Researchers at the Case Western Reserve School of Medicine have found that semaglutide, a popular diabetes and weight-loss ...

Semaglutide improved time spent in glycemic range, time below rate and reduced body weight with low rates of hypoglycemia ...

Incidence rates of composite of death, MI, stroke were lower, but not significantly so, for patients treated with semaglutide ...

A 68-week phase 3 trial found that coadministered cagrilintide and semaglutide led to significant and clinically meaningful ...

Semaglutide therapy in patients with obese heart failure leads to marked weight loss and notable gains in mood, function, and ...

A new clinical trial found that taking a popular diabetes and weight-loss drug once weekly significantly improves blood sugar ...

The researchers found that after 64 weeks, participants had a mean weight loss of −16.7%, with a mean semaglutide dose of 1.08mg/week. (HealthDay News) — Weight loss treatment combining ...

A specific group of nerve cells in the brain stem appears to control how semaglutide affects appetite and weight -- without causing nausea. A specific group of nerve cells in the brain stem ...

A specific group of nerve cells in the brain stem appears to control how semaglutide affects appetite and weight – without causing nausea. The discovery, made at the University of Gothenburg, could ...